Novo Nordisk (NVO)
NYSE:NVO
Want to see NVO full AI Analyst Report?
NVO Stock Chart & Stats
$40.52
$1.93(2.32%)
At close: 4:00 PM EST
$40.52
$1.93(2.32%)
Day’s Range― - ―
52-Week Range$35.12 - $74.82
Previous CloseN/A
Volume3.65M
Average Volume (3M)14.09M
Market Cap
$193.40B
Enterprise Value$1.39T
Total Cash (Recent Filing)$21.63B
Total Debt (Recent Filing)$146.38B
Price to Earnings (P/E)10.2
Beta1.22
Next Earnings
Aug 05, 2026EPS Estimate
0.82Next Dividend Ex-DateN/A
Dividend Yield3.58%
Share Statistics
EPS (TTM)27.45
Shares Outstanding3,390,128,000
10 Day Avg. Volume13,518,632
30 Day Avg. Volume14,085,041
Financial Highlights & Ratios
PEG Ratio8.17
Price to Book (P/B)7.42
Price to Sales (P/S)4.66
P/FCF Ratio49.64
Enterprise Value/Market Cap7.21
Enterprise Value/Revenue4.25
Enterprise Value/Gross Profit5.19
Enterprise Value/Ebitda7.50
Forecast
1Y Price Target
$46.00Price Target Upside13.52% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)3.33
Revenue Forecast (FY)$45.10B
Bulls Say, Bears Say
Bulls Say
Obesity Franchise ExpansionRegulatory backing for a high‑dose single‑dose Wegovy pen materially strengthens product convenience and clinical differentiation. This durable improvement in dosing and planned EU launch should deepen patient uptake, extend market penetration, and entrench Novo Nordisk’s leadership in the fast‑growing obesity segment against new entrants.
Exceptional Profitability And MarginsConsistently very high gross and net margins reflect strong pricing power, manufacturing scale and differentiated biologic therapies. High margins support sustained R&D investment, dividends and buybacks, providing structural cash to fund pipeline and shareholder returns even if top‑line growth moderates.
Pipeline Diversification Into Rare DiseaseA successful Phase‑3 in sickle cell disease and planned regulatory filing broaden revenue sources beyond GLP‑1 and obesity. Orphan designations and meaningful clinical benefit create a durable specialty franchise with high pricing and payer interest, reducing single‑product concentration and supporting long‑term growth.
Bears Say
Rising LeverageMaterial rise in leverage reduces financial flexibility and raises interest‑rate sensitivity, limiting the firm's ability to absorb shocks or fund opportunistic M&A without higher funding costs. Higher debt increases risk to capital allocation priorities and could constrain investment or shareholder returns if macro or pricing pressures intensify.
Weakened Free Cash Flow ConversionLower and more volatile free cash flow versus prior years means less predictable internally generated cash for dividends, buybacks and reinvestment. Persistent weaker cash conversion suggests heavier reinvestment or working‑capital drag, increasing reliance on debt or capital markets and reducing margin for error in stressed scenarios.
Concentration Risk In GLP‑1 And U.S. ExposureHeavy dependence on GLP‑1/obesity products and large U.S. exposure concentrates commercial risk: payer actions, pricing pressures or competitor launches in core markets can disproportionately affect revenues. With growth moderating from the 2022–2024 surge, sustaining past expansion rates becomes harder and volatility may persist quarter to quarter.
Novo Nordisk News
NVO FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was $35.12 and its highest was $74.82 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $193.40B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Aug 05, 2026 which is in 46 days.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on May 06, 2026. The company reported $1.043 earnings per share for the quarter, beating the consensus estimate of $0.884 by $0.159.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of $1.217 which represents an annual dividend yield of 3.58%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.82.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of $1.043 in its last earnings report, beating expectations of $0.884. Following the earnings report the stock price went up 1.984%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in NVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novo Nordisk Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$46.00 (13.52% Upside)
$46.00 (13.52% Upside)
Blogger Sentiment
Bullish
NVO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 21.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bullish
Bullish news 94%
Bearish news 6%
Bearish news 6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.64%
12-Months-Change
Fundamentals
Return on Equity
66.36%
Trailing 12-Months
Asset Growth
21.75%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
NVO Company Deck
NVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial momentum in obesity and GLP-1 franchises (notably the successful Wegovy pill launch, robust GLP-1 volume share, and meaningful R&D readouts such as CagriSema and zenagamtide) alongside solid cash generation and shareholder returns. Offsetting these positives are substantial near-term headwinds driven by pricing pressure, policy impacts (MFN/MFP), loss of exclusivity risk, margin compression and a conservative 2026 outlook (adjusted sales and operating profit guidance of -5% to -13% CER). Management is bullish on long-term market expansion and pipeline potential but explicit near-term guidance and exceptional costs temper the tone. Overall, positives (product launches, R&D wins, market leadership and cash generation) are significant, but the company has signaled a pronounced near-term earnings challenge driven by pricing and policy — producing a balanced, watchful outlook.View all NVO earnings summariesNVO Stock 12 Month Forecast
Average Price Target
$46.00
▲(13.52% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.60% Mutual Funds
4.40% Other Institutional Investors
93.75% Public Companies and Individual Investors